文献速递甲状腺疾病骨质疏松与钙磷/甲状旁腺

甲状腺癌促甲状腺激素抑制治疗女性中放射性椎体骨折高患病率

High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma.
PubMed 文献 · J Clin Endocrinol Metab · 2018-01-01

横断面研究纳入179例因分化型甲状腺癌行甲状腺切除术后接受左甲状腺素治疗的女性,评估放射性椎体骨折患病率及决定因素。椎体骨折总体患病率为28.5%,TSH目标<0.5 mU/L组患病率44.6%,显著高于0.5-1.0 mU/L组24.0%和>1.0 mU/L组4.3%。椎体骨折与TSH水平<1.0 mU/L、骨质疏松、年龄及左甲状腺素治疗时长独立相关。

要点

  • TSH抑制治疗女性放射性椎体骨折患病率高达28.5%
  • TSH<0.5 mU/L组椎体骨折患病率44.6%,显著高于其他两组
  • 椎体骨折与TSH<1.0 mU/L、骨质疏松、年龄和治疗时长独立相关

核心结论

  • 在接受长期抑制性左甲状腺素治疗的分化型甲状腺癌女性中,放射性椎体骨折患病率较高。

研究设计与样本

  • 横断面研究纳入179例因分化型甲状腺癌行甲状腺切除术后正在接受左甲状腺素治疗的连续女性,中位年龄59岁,其中178例为绝经后。
  • 按TSH目标水平分为三组:组1 TSH<0.5 mU/L(n=83)、组2 TSH 0.5-1.0 mU/L(n=50)、组3 TSH>1.0 mU/L(n=46),评估放射性椎体骨折和骨密度。

主要发现

  • 51例患者(28.5%)发现椎体骨折,组1患病率44.6%,显著高于组2的24.0%和组3的4.3%(P<0.001)。
  • 组1中骨密度正常、骨量减少或骨质疏松患者的椎体骨折患病率无显著差异;组2和组3中骨质疏松患者的椎体骨折较骨量减少或骨密度正常者更常见。
  • 在全人群中,椎体骨折与TSH水平<1.0 mU/L、腰椎或股骨颈或全髋的骨密度诊断骨质疏松、患者年龄及左甲状腺素治疗时长显著且独立相关。

关键数值与推荐

  • 椎体骨折总体患病率28.5%(51/179)。
  • 组1(TSH<0.5 mU/L)椎体骨折患病率44.6%,组2(TSH 0.5-1.0 mU/L)24.0%,组3(TSH>1.0 mU/L)4.3%,组1与组2、组3比较P<0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Bone loss and nonvertebral fractures have been reported in patients with differentiated thyroid carcinoma (DTC) undergoing thyroid-stimulating hormone (TSH) suppressive therapy. Radiological vertebral fractures (VFs) are an early and clinically crucial marker of bone fragility. OBJECTIVE AND DESIGN: A cross-sectional study to evaluate the prevalence and determinants of radiological VFs in women receiving l-thyroxine (L-T4) therapy for DTC. PATIENTS AND INTERVENTIONS: A total of 179 consecutive women (median age, 59 years; n = 178 postmenopausal) who had undergone thyroidectomy for DTC and were currently receiving L-T4 were evaluated for radiological VFs and bone mineral density (BMD). There were three TSH target levels [<0.5 mU/L, group 1 (n = 83); 0.5 to 1.0 mU/L, group 2 (n = 50); >1.0 mU/L, group 3 (n = 46)]. RESULTS: VFs were found in 51 patients (28.5%), with significantly (P < 0.001) higher prevalence in group 1 (44.6%) as compared with group 2 (24.0%) and group 3 (4.3%). VF prevalence was not significantly different among patients in group 1 with normal BMD, osteopenia, or osteoporosis, whereas in groups 2 and 3, VFs were more frequent in patients with osteoporosis than in those with either osteopenia or normal BMD. In the whole population, VFs were significantly and independently associated with TSH level <1.0 mU/L; densitometric diagnosis of osteoporosis at lumbar spine, femoral neck, or total hip; age of patients; and duration of L-T4 therapy. CONCLUSION: The prevalence of VFs was high in women with DTC who were undergoing long-term, suppressive L-T4 therapy.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Mazziotti G, Formenti AM, Frara S, et al. High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma. J Clin Endocrinol Metab. 2018. PMID: 29121201. doi:10.1210/jc.2017-01986

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。